As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Eli Lilly and Company: Hsbc Holdings PLC, REX Advisers LLC, Raymond James Financial Inc., Beacon Pointe Advisors LLC, CTC LLC, Toronto Dominion Bank, Tudor Investment Corp ET AL, Millennium Management LLC, Man Group plc, Caption Management LLC, Citadel Advisors LLC, Balyasny Asset Management L.P., Boothbay Fund Management LLC, Alphadyne Asset Management LP, 683 Capital Management LLC, J. Goldman & Co LP, Game Creek Capital LP, Farallon Capital Management LLC, Susquehanna Advisors Group Inc., B Group Inc., National Bank of Canada FI, Royal Bank of Canada, ADAPT Investment Managers SA, Squarepoint Ops LLC, Walleye Trading LLC, PEAK6 LLC, Maven Securities LTD, Barclays PLC, Volterra Technologies LP, Marshall Wace LLP, Walleye Capital LLC, Hudson Bay Capital Management LP, Bank of Nova Scotia, Citigroup Inc., Wells Fargo & Company MN, Jane Street Group LLC, DRW Securities LLC, Capital Markets Trading UK LLP, Marex Group plc, XY Capital Ltd, Group One Trading LLC, Simplex Trading LLC, Allianz Asset Management GmbH, LPL Financial LLC, JPMorgan Chase & Co., Twin Tree Management LP, Lido Advisors LLC, Bank of New York Mellon Corp, Goldman Sachs Group Inc., Monaco Asset Management SAM, BNP Paribas Financial Markets, Gladius Capital Management LP, Mission Wealth Management LP, and Valeo Financial Advisors LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.